Actas dermo-sifiliograficas最新文献_第7页

Bilateral Hand Swelling as a Sign of Systemic Amyloidosis 双侧手肿胀是系统性淀粉样变的征象。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104577

M.A. Sirvent-Sáez, A.I. Sánchez-Del-Campo, D. Moreno-Ramírez

引用次数: 0

Paramedian Forehead Flap With Intraoperative Frontal Expansion 术中额部扩张的旁位前额皮瓣。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104578

D. Moreno-Ramírez , A. Fernández-Orland , F. Vizcaíno , L. Ferrándiz

引用次数: 0

Traditional Practices in Dermatology and Wound Care: Are They Evidence-Based? 皮肤病学和伤口护理的传统做法：它们是基于证据的吗？

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-05-01 Epub Date: 2025-12-18 DOI: 10.1016/j.ad.2025.104573

A. García-Mares , E. Conde Montero

引用次数: 0

Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa secukinumab与阿达木单抗治疗中重度化脓性汗腺炎的成本-后果分析

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-05-01 Epub Date: 2025-12-20 DOI: 10.1016/j.ad.2025.104582

A. Martorell , A. Molina-Leyva , A. Jiménez Morales , C. Blanch

{"title":"Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa","authors":"A. Martorell , A. Molina-Leyva , A. Jiménez Morales , C. Blanch","doi":"10.1016/j.ad.2025.104582","DOIUrl":"10.1016/j.ad.2025.104582","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Treatment for moderate-to-severe HS includes biologic therapies (adalimumab and secukinumab), resulting in increased disease management costs. Our aim was to estimate the difference between secukinumab and adalimumab in terms of pharmacological costs and costs per responding patient 1 year into therapy from the Spanish National Health System (NHS) perspective.</div></div><div><h3>Material and methods</h3><div>We designed a decision tree comparing different treatment sequences, starting with a different first-line therapy. Patients switched arms based on achieving HS clinical response ≥50% (based on the SUNSHINE, SUNRISE, and PIONEER clinical trials results). A cohort of 100 patients was considered. Only treatment costs in € (2023 base year) were considered for the analysis. A panel of experts validated the model structure and parameters.</div></div><div><h3>Results</h3><div>After 52-weeks into therapy, treatment sequences in the secukinumab group resulted in a total cost of €1,198,912, corresponding to €16,858 per responder. Total costs in the adalimumab treatment group were 2.5% higher, corresponding to €19,701 per responder. A total of 80% of responders who start treatment with secukinumab do not change treatment, while only 31% of responders who start treatment with adalimumab stay on the same treatment.</div></div><div><h3>Conclusions</h3><div>The results of our financial assessment can help decision makers in selecting the most efficient therapeutic approach for treating patients with moderate-to-severe HS and poses secukinumab as a suitable therapeutic option for the Spanish NHS.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104582"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phenotypes in Symptomatic Dermographism 症状性皮肤特征的表型。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-05-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ad.2025.104566

M. Prados-Castaño, M. Reguero Capilla, E. Menéndez-Rivero, L. Ruiz Del Barrio

引用次数: 0

Translation, Cross-cultural Adaptation, Correlation With Other PROMs and Validation of the MF/SS-CTCL-QoL Questionnaire on Quality of Life in Mycosis Fungoides (MF) and Sézary Syndrome (SS) MF/SS- ctcl - qol真菌病（MF）和ssamzary综合征（SS）生活质量问卷的翻译、跨文化适应、与其他PROMs的相关性和验证。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-05-01 Epub Date: 2025-12-23 DOI: 10.1016/j.ad.2025.104584

M.M. Onteniente-Gomis , S.I. Palencia Perez , F.J. Ortiz de Frutos , C.M. García Álvarez , C. Martin Arriscado Arroba , C. Varela Rodriguez , P.L. Ortiz-Romero

{"title":"Translation, Cross-cultural Adaptation, Correlation With Other PROMs and Validation of the MF/SS-CTCL-QoL Questionnaire on Quality of Life in Mycosis Fungoides (MF) and Sézary Syndrome (SS)","authors":"M.M. Onteniente-Gomis , S.I. Palencia Perez , F.J. Ortiz de Frutos , C.M. García Álvarez , C. Martin Arriscado Arroba , C. Varela Rodriguez , P.L. Ortiz-Romero","doi":"10.1016/j.ad.2025.104584","DOIUrl":"10.1016/j.ad.2025.104584","url":null,"abstract":"<div><h3>Background</h3><div>MF/SS-CTCL-QoL is the first specific questionnaire to measure the quality of life (QoL) of patients with mycosis fungoides (MF) and Sézary syndrome (SS). It was developed by the Cutaneous Lymphoma Foundation.</div></div><div><h3>Objectives</h3><div>(1) Translate and cross-culturally adapt the MF/SS-CTCL-QoL to Spanish (Spain). (2) To study correlation and concordance of the MF/SS-CTCL-QoL with PROM (Patient Reported Outcome Measurements): EORTC QLQ-C30, Dermatology Life Quality Index (DLQI) and Skindex-29.</div></div><div><h3>Material and methods</h3><div>Using a 10-step procedure, including expert meetings and surveys of adult patients with MF or SS, a Spanish version of the MF/SS-CTCL-QoL was developed. Subsequently, its comprehensibility, completeness and relevance were evaluated. A correlation study was performed using Spearman's rho coefficient and concordance using the intraclass correlation coefficient (ICC), between MF/SS-CTCL-QoL and the EORTC QLQ-C30, DLQI and Skindex-29 questionnaires.</div></div><div><h3>Results</h3><div>Translation was satisfactory for professionals and patients, with minimal adaptations required. Excellent correlation (0.8499) was observed between MF/SS-CTCL-QoL and Skindex-29, good (0.7394) with DLQI and poor (0.5602) with EORTC QLQ-C30. Agreement was moderate (0.699) with DLQI, significant (0.865) with Skindex-29 and low (0.568) with EORTC QLQ-C30.</div></div><div><h3>Conclusions</h3><div>The Spanish version of MF/SS-CTCL-QoL represents a useful tool for the clinical management of patients with MF and SS. It is linguistically equivalent to the original, assesses the same dimensions with an adequate level of comprehensibility. There is an excellent correlation with Skindex-29, good with DLQI and poor with EORTC QLQ-C30.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104584"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145832070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxic Epidermal Necrolysis Due to Pembrolizumab-Associated Chemotherapy 派姆单抗相关化疗引起的中毒性表皮坏死松解。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-05-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ad.2025.104570

L. Bernal Masferrer, B. Aldea Manrique, M. Claudia Matei, T. Gracia Cazaña

引用次数: 0

Accessibility as a Key Factor in the Clinical Evolution and Therapeutic Management of Patients With Hidradenitis Suppurativa 可及性是化脓性汗腺炎患者临床发展和治疗管理的关键因素。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-04-01 Epub Date: 2025-12-31 DOI: 10.1016/j.ad.2025.104589

F.J. León Pérez , C. García Moronta , S.M. Haselgruber de Francisco , D. Muñoz Barba , C. Cuenca Barrales , S. Arias Santiago , A. Molina Leyva

{"title":"Accessibility as a Key Factor in the Clinical Evolution and Therapeutic Management of Patients With Hidradenitis Suppurativa","authors":"F.J. León Pérez , C. García Moronta , S.M. Haselgruber de Francisco , D. Muñoz Barba , C. Cuenca Barrales , S. Arias Santiago , A. Molina Leyva","doi":"10.1016/j.ad.2025.104589","DOIUrl":"10.1016/j.ad.2025.104589","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory disease with a substantial impact on quality of life. Accessibility to specialized units and referral methods may significantly influence clinical characteristics and therapeutic decisions. This study aims to analyze the relationship between geographical distance, referral method, and the clinical and therapeutic characteristics of patients with HS.</div></div><div><h3>Materials and methods</h3><div>This was a cross-sectional study including 557 consecutive patients treated between 2017 and 2024 at the HS Unit of Hospital Universitario Virgen de las Nieves. Clinical, demographic, and treatment-related variables were collected. Geographical distance was calculated based on postal codes, and differences between referral methods (teledermatology vs conventional) were analyzed using descriptive and comparative statistical methods.</div></div><div><h3>Results</h3><div>Patients residing at greater distances presented with more severe disease (Hurley stage III, higher IHS4 scores) and poorer quality of life (DLQI). They also required more intensive treatment regimens, with increased use of biological immunomodulatory drugs. Patients referred via teledermatology were generally younger, had a shorter disease duration, and exhibited milder disease severity at the time of consultation.</div></div><div><h3>Conclusions</h3><div>Geographical distance and referral method may significantly influence the clinical and therapeutic profiles of patients with HS. These findings underscore the need for strategies to improve accessibility and ensure equitable management. Teledermatology emerges as a valuable tool for early-stage cases, although it should be complemented with in-person assessments for more complex cases.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104589"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145891776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Artificial Intelligence in Cosmetic Dermatology 皮肤病学基础模型：人工智能的进展。叙述性评论。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-04-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ad.2025.104560

D.E. Pimienta-Rosero , E.Y. Benavides-Tulcán , D.C. Fajardo-Murcia

引用次数: 0

Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning 1% Clascoterone治疗痤疮：疗效、安全性和治疗定位的综述”。

IF 2.8

Actas dermo-sifiliograficas Pub Date : 2026-04-01 Epub Date: 2025-12-24 DOI: 10.1016/j.ad.2025.104587

P. Balado-Simó , M. Brufau-Cochs , D. Morgado-Carrasco

引用次数: 0